News, Infos & good to know Forum: Community User: Lirumlarum1

Und NantKwest hat immer noch nur eine Marktkapitalisierung von rund 760 Millionen Euro, das ist unfassbar günstig.

Demnach ist auch bald ein Update der Merkell Cell Carcinom Linie zu erwarten.

Auf Seite 14A steht, dass ein Patient mit Merkell Cell Carcinom seit 4! Jahren ohne neuen Krebs Befund ist. Und das obwohl dieser Patient vorher schon fehlgeschlagene standard Behandlungen und Chemotherapie bekommen hatte.

Investors Update November 2020: https://nantkwest.com/wp-content/uploads/2020/11/NantKwest-Corporate-Deck-v15-11-9-20lr.pdf

ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study First two cohorts fully enrolled; Low dose cohort reports no serious adverse events (SAE), high dose cohort safety analysis ongoing Subject screening is ongoing for Phase I expansion cohorts Phase 2 / 3 hAd5 COVID-19 trial in design   CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Nov. 10, 2020-- ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have administered their second-generation bivalent, human adenovirus (hAd5) COVID-19 vaccine candidate in a Phase 1 trial with no serious adverse events (SAE) reported in the low dose cohort, safety is ongoing for the high dose cohort. The trial, being conducted at Hoag Hospital in Newport Beach, California, enrolled 20 volunteers across two dose levels and the subject screening for the Phase I expansion cohort is ongoing. Developed by ImmunityBio and manufactured by NantKwest, this second generation hAd5-vector vaccine is unique in targeting both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins. The vaccine is designed to generate both antibodies and CD4+ and CD8+ T cell responses, all of which we believe are necessary for generating long-term immune memory. A recent study of responses of T cells from convalescent plasma collected from previously-infected SARS-CoV-2 patients demonstrated that the hAd5 vaccine could stimulate recall of SARS-CoV-2 specific CD4+ and CD8+ memory T cells from these patients to the S and N proteins delivered by the hAd5-COVID-19 vaccine. This finding of immune recall suggests that the hAd5 COVID-19 vaccine could potentially elicit cell-mediated immune responses in convalescent, previously infected patients to stimulate and boost memory T cells specific to SARS-CoV-2. “We are grateful to the many volunteers who are participating in this important Phase 1 study of our COVID-19 vaccine candidate,” said Patrick Soon-Shiong, M.D., Chairman and CEO of ImmunityBio. “Given the urgent need for long-term protection from SARS-CoV-2 viruses and the alarming increase of infection in our country, we’re heartened by what we’ve observed so far and hope to be able to move quickly to a Phase 2/3 randomized, double-blind control trial, involving a larger group of volunteers including persons previously infected with SARS-CoV-2.”

ImmunityBio’s hAd5 COVID-19 Vaccine Candidate Stimulates Memory T-Cell Recall in Patients Infected with SARS-CoV-2 Study shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2 infection, demonstrating that the S and N antigens from the vaccine are recognized by SARS-COV-2 reactive human T cells Study results suggest this next-generation human adenovirus 5 (hAd5) vaccine, which delivers both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, stimulates memory CD4+ and CD8+ T-cells, both of which may be critical for clearing virus infected cells. Together with earlier studies in pre-clinical models, which demonstrate the vaccine’s immunogenicity, these findings support the further use of this vaccine as a therapeutic in newly infected patients to limit lateral transmission of the disease. T-cell response may provide long-term immunity and mitigate waning short-lived antibodies against the coronavirus. CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 9, 2020-- ImmunityBio, Inc. a privately-held, clinical-stage immunotherapy company, today announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which shows memory T-cell recall from patients previously infected with SARS-CoV-2 virus. The ability to stimulate SARS-CoV 2 specific T-cells, which recognize the N and S proteins, is a crucial part of the novel design of ImmunityBio’s vaccine candidate. The antibody- and T cell-based vaccine seeks both to provide protection for the uninfected population and also the potential to clear virally infected cells in infected subjects. It is unclear how long antibodies may provide protection. With the production of both antibodies and T cells, the potential exists for long-term, durable immunity. The results of this study were published in medRxiv (“Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2”). ImmunityBio’s vaccine candidate targets both the spike (S) and nucleocapsid (N) proteins (hAd5 S + N) of SARS-CoV-2 to activate a multi-pronged attack by the immune system. This is distinct from most vaccine candidates currently in late-stage clinical trials, which target S alone. Recent reports suggest that antibodies to S may be vulnerable to reduced effectiveness because of emerging new mutations, as well as uncertainty over the longevity of the antibody response over time. The hAd5 bivalent COVID-19 vaccine induces T cell immunity and could provide long-term protection against the virus as the antibodies wane over time. An additional distinctive feature of the ImmunityBio vaccine candidate design is its use of a second-generation human adenovirus serotype 5 (hAd5) that has been shown to effectively deliver antigens even in the presence of preexisting adenovirus immunity which is present in up to roughly 60% of the populationi. “As the virus continues to spread at an alarming rate, it is important that we develop COVID-19 vaccines that not only provide the population with protection from new infection through antibodies that block viral entry into cells, but also establish a robust T cell immune response to clear the virus from infected cells,” said Patrick Soon-Shiong, M.D., Chairman and CEO of ImmunityBio. “This study suggests that our vaccine candidate has the potential to both serve as a protective vaccine for the uninfected population, and, potentially, also as a therapeutic to enhance the speed of viral clearance in the newly diagnosed, positively infected patient by T cell clearance of infected cells. We plan to study this hypothesis in our ongoing clinical trials to explore whether by stimulating SARS-CoV-2-specific T cells, our vaccine could induce rapid clearance of the virus from a newly diagnosed patient, and reduce the risk of airborne transmission from infected patients to healthy contacts.” The manuscript detailing these preclinical data is available on preprint server medRxiv at [https://www.medrxiv.org/content/10.1101/2020.11.04.20225417v1] and is concurrently undergoing scientific peer-review for potential publication. A previously announced preclinical study showed that ImmunityBio’s hAd5 S-Fusion + N-ETSD (hAd5 COVID-19) vaccine candidate elicits both T-cell immunity and neutralizing antibodies in a murine pre-clinical model [“ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins”]. The present study demonstrates the CD4+ and CD8+ memory T cells of previously infected SARS-CoV-2 patients, but not unexposed individuals, recognize SARS-CoV-2 antigens expressed by hAd5 S-Fusion + N-ETSD infected dendritic cells in vitro. These data support the hypothesis that SARS-CoV-2 antigens delivered to cells by the next generation hAd5 platform are expressed in human cells in a conformationally relevant manner and available to elicit an adaptive immune response, critical for vaccine efficacy. About the Phase I Clinical Trial ImmunityBio and NantKwest are currently enrolling 35 healthy adults aged 18 to 55 years old in the Phase 1 study for the hAd5-COVID-19 vaccine candidate (NCT04591717). hAd5-COVID-19 will be administered as both a prime and boost using the same vector platform to enable sustained protection against SARS-CoV-2. The study’s main objective is to examine the safety of and reactogenicity to two doses of the vaccine. The companies are also pursuing development for oral, inhalational, and intranasal administration of hAd5. For more information about the trial or to enroll in it, please contact clinicalresearch@hoag.org. About the Second-Generation hAd5 Adenovirus Platform Based on ImmunityBio’s ongoing development of an adenovirus-based vaccine for the treatment of cancer (The NANT Cancer Vaccine), the company has developed a unique second-generation COVID-19 vaccine, distinctive in multiple aspects of design from the current COVID-19 vaccines in late stage clinical trials, including the (1) vector platform, (2) the immunogenic SARS-CoV-2 proteins selected, (3) the balanced antibody and T cell immune activation based on molecular trafficking of the SARS-CoV-2 protein, (4) addressing multiple modes of administration to achieve mucosal, antibody and long-term cell mediated immunity, and (5) overcoming cold-chain limitations by developed refrigerated and room-temperature stable vaccines. A.  Scientific differentiation of hAd5 over existing adenoviral vector approaches:       Compared to current adenovirus vector platforms in Phase 3 clinical trials for COVID-19, ImmunityBio’s hAd5 has four deletions, enabling delivery of the transgene COVID-19 proteins even in the presence of pre-existing adenovirus immunity. Clinical studies in cancer patients have shown the capability of inducing CD4+ and CD8+ T cell responses following multiple subcutaneous injections of hAd5 in patients with proven adenoviral immunity.      B.  Demonstrated use of hAd5 vector delivery platform for other potential outbreaks of known viruses as well as novel or previously unrecognized viruses, with demonstrated capability for rapid development, pre-clinical testing and GMP manufacture:    ImmunityBio has reported the successful rapid development of hAd5 as a vaccine during the H1N1 outbreak in 2009. Details will be discussed below. In addition, ImmunityBio has published on the successful pre-clinical development of vaccines for HIV, SIV, Chikungunya, Lassa Fever, and, Influenza.      C.  NANT Cancer Vaccine and QUILT Clinical Trials:    ImmunityBio has studied the hAd5 platform extensively in over 150 patients with cancer across 13 Phase 1 / 2 trials. The transgenes expressed include: hAd5-CEA, hAd5-PSA, hAd5-MUC1, hAd5-Brachyury. In these studies at the National Cancer Institute (NCI) and academic centers, successful antigen specific CD4+ and CD8+ T cells were induced even in the presence of previous adenoviral immunity. These studies, a component of the NANT Cancer Vaccine and QUILT clinical trials, are ongoing.

https://www.google.com/amp/s/www.t-online.de/unterhaltung/stars/id_88902820/tid_amp/-jeopardy-legende-alex-trebek-80-an-krebs-gestorben.html

Did Patrick Soon-Shiong attempt to scoop President Barack Obama’s State of the Union address? Several days before Obama announced the federal government’s moonshot to cure cancer, Soon-Shiong put out a draft press release, claiming that the White House, NIH, FDA and pharmaceutical companies have united in “Cancer MoonShot 2020,” an immunotherapy clinical trials program he devised. Soon-Shiong, founder and CEO of NantWorks and the Chan Soon-Shiong Institute of Molecular Medicine, ultimately announced his moonshot on Jan. 11, a day before Obama announced his. Soon-Shiong Says FDA & NCI are Onboard For His Moonshot; Feds Deny Involvement Government agencies said the biotechnology billionaire Patrick Soon-Shiong had overstated the extent of their involvement in “Cancer MoonShot 2020,” the immunotherapy clinical trials program he put together. In an in-depth conversation with Matthew Bin Han Ong, a reporter with The Cancer Letter, Soon-Shiong said that while his program doesn’t seek federal funds, it has the support of NCI and FDA officials. Soon-Shiong said he and Vice President Joe Biden met to discuss their interlocking missions and are now pursuing them. https://cancerletter.com/patrick-soon-shiong/

https://mobile.twitter.com/drpatsoonshiong/status/1322939477044592641?s=21

Dr. Pat Soon-Shiong @DrPatSoonShiong ·5 Std. Our T Cell COVID vaccine out the gate!Thanks to our hard working incredible scientists and entire team at @immunitybio and @nantkwest who worked tirelessly to make this happen and to the participants in the study. @hoaghealth #coronavirus New Novel "Stealth" COVID-19 Vaccine Starts Clinical Trial in OC spectrumnews1.com

PSS is going to be speaking at a virtual conference in South Africa on Nov. 11th re “biopharmaceuticals: global partnerships, localisation and technology convergence.” 2/2 A SA born surgeon living in the USA – and one of the most successful entrepreneurs in the healthcare sector, Prof. Patrick Soon-Shiong – is amongst the top speakers at the 7th Biennial Conference taking place on 11 & 12 November 2020. https://mobile.twitter.com/csir/status/1322130812251373569?s=21

Richard Adcock, Chief Executive Officer von NantKwest, Inc., scheint eine leere erste Erklärung über das wirtschaftliche Eigentum eingereicht zu haben. Dieses Formular wird normalerweise als Auftakt für einen leitenden Angestellten des Unternehmens eingereicht, der entweder Optionen erhält oder Unternehmensaktien kauft, sodass möglicherweise noch mehr von Adcock kommt.

Soon-Shiong Steps Aside As CEO Of NantKwest By Howard Fine Monday, October 26, 2020 Billionaire Patrick Soon-Shiong has stepped aside as chief executive of Culver City biotech firm NantKwest Inc., handing the reins to longtime health care executive Richard Adcock effective immediately, the company announced late on Oct. 26. Soon-Shiong becomes executive chairman of NantKwest’s board and retains roughly two-thirds ownership of the company with more than 67 million shares. Adcock was formerly chief executive of Verity Health Systems, the El Segundo-based hospital chain that filed for bankruptcy in 2018 and sold off its hospitals earlier this year. The relationship between Soon-Shiong and Adcock extends back at least five years as Soon-Shiong’s NantWorks family of companies (which includes NantKwest) had invested more than $300 million in Verity. NantWorks was also majority owner of Integrity Health, a management company which in 2015 was brought in to run Verity. When Verity filed for bankruptcy, Soon-Shiong and Nantworks were the company’s largest creditor. As the bankruptcy wound down, Soon-Shiong purchased one of Verity’s Hospitals, St. Vincent Medical Center in L.A.’s Westlake district, for $135 million. Prior to his tenure at Verity, Adcock served as chief innovation officer for Sanford Health of Sioux Falls, S.D., a major rural nonprofit health care system with more than 382 locations and 28,000 employees throughout the U.S. “I’m excited to have Rich, with his extensive experience and unwavering commitment to innovation and operations, at the helm of NantKwest at a crucial time for the company and for the entire health care industry,” Soon-Shiong said in the announcement.  “Not only is Rich uniquely qualified to take on this role, but having worked with him for several years, I am confident that he is the right leader to advance NantKwest and its mission. I intend to work closely with him and continue to maintain an active role in achieving NantKwest’s mission to harness the power of natural killer cells and the human immune system to transform the treatment of cancers and serious infectious diseases.” Soon-Shiong remains chief executive of ImmunityBio, a privately held company that has worked with NantKwest to develop immune system-based drugs to combat a range of diseases, including cancer and, more recently, Covid-19.  Both companies have been participating in the Trump Administration’s “Warp Speed” program to bring vaccines to market as rapidly as possible to fight Covid-19. “I am thrilled to be joining Dr. Soon-Shiong and the NantKwest team on the quest to cure cancer and infectious diseases using natural killer cell therapy,” Adcock said in the announcement. “I look forward to using my experience in health care research and delivery to help accelerate NantKwest’s growth.” https://labusinessjournal.com/news/2020/oct/26/soon-shiong-steps-aside-ceo-nantkwest-former-healt/

NantKwest COVID-19 Candidate, And Other News: The Good, Bad And Ugly Of Biopharma https://www.google.com/amp/s/seekingalpha.com/amp/article/4381185-nantkwest-covidminus-19-candidate-and-news-good-bad-and-ugly-of-biopharma

Dr. Pat Soon-Shiong @DrPatSoonShiong Can’t wait to see final results of Covid viral challenge after our human adenovirus vaccine #hAd5 vaccine covering both the outer spike and inner nucleocapsid of Covid. Coming soon. First wave of next generation Covid vaccines now out the gate!!! #COVID #vaccine